- The US jobs report exceeded expectations, with non-farm payrolls surging over 250k.
- The unemployment rate declined for the second consecutive month to 4.1%.
- Equities rebounded on a fresh recommendation, with Chinese ADRs recovering from Thursday's selloff.
- Rivian shares tumbled as the company slashed its production forecast for the year.
US indices opened sharply higher, driven by a buoyant US jobs report that tempered recession fears. Non-farm payrolls surged 254k in September, while the unemployment rate dipped to 4.1%. This robust data points to potential strength in consumer spending and GDP growth in the third and fourth quarters, defying recent expectations of a slowdown.
The US500 is just 0.6% shy of its all-time highs set last week. Today's trading saw the index test the 5800 level, coinciding with a 113.0% Fibonacci retracement of the recent summer rally. Concurrently, bond yields have surged, as reflected in falling bond prices. If the uptrend persists, the next significant target is around 5900; support lies at 5725.
Source: xStation5
Company News:
- CVS Health (CVS.US) gained over 3% on plans to potentially split into two divisions: pharmaceutical and insurance. TD Cowen upgraded the stock on improved prospects for its Medicare Advantage plan.
- Rivian Automotive (RIVN.US) shed nearly 4% after slashing its production forecast for the year due to supply chain constraints. The company delivered 10k vehicles in Q3, missing analyst estimates.
- Despite Rivian's problem, Amazon (AMZN.US) is up today by more than 3% as it plans to boost workforce by 250k for Holidays this year which indicate a robust retail sales in coming months.
- Chinese ADRs rebounded after Thursday's selloff, with Alibaba, JD, and Tencent posting gains.
STMicroelectronics shares down 14% amid mixed future outlook📉
US100 gains 0.5% 📈Kansas City Fed Index above estimates
Stock of the Week - Merck & Co Inc (23.10.2025)
Beyond Meat after the sell-off📉Is short squeeze still possible?
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
